Lab Test

BCR/ABL Gene Rearrangement Test

BCR/ABL Qualitative Test, BCR-ABL Gene Rearrangement Test, BCR ABL Gene Rearrangement Test, CML, t(9;22), chronic myelogenous leukemia , ALL , acute lymphoblastic leukemia, major, minor, breakpoint, EPIC: LAB6378, SOFT: GBCRG

Test Codes



Samples should be drawn as early in the day as possible so they can be delivered to the Laboratory the same day.

Specimen Collection Criteria

Collect: Blood OR Bone Marrow

  • Blood: 10 mL whole blood in Lavender-top EDTA tubes. (Min: 5.0 mL)
  • Bone Marrow: 1.0 mL bone marrow aspirate in a Lavender-top EDTA tube. (Min: 0.5 mL)
  • Other specimen types require the approval of the Medical or Technical Director.

Physician Office/Draw Specimen Preparation

Do not freeze specimens. Maintain specimens at room temperature (20-26°C or 68-78.8°F) and transport to the Laboratory within 4-6 hours of collection.  

Preparation for Courier Transport

Transport: Whole blood or bone marrow aspirate at room temperature (20-26°C or 68-78.8°F).

Rejection Criteria

  • Frozen specimens. 
  • Unlabeled tubes. 
  • Specimens collected in heparin (Green-top), clot tubes (Red-top) ACD anti-coagulant tubes, or SST tubes.     

In-Lab Processing

Do not freeze specimens. Maintain specimen refrigerated (2-8°C or 36-46°F) prior to testing. 


Specimen Stability for Testing:

Room Temperature (20-26°C or 68-78.8°F): 6 hours
Refrigerated (2-8°C or 36-46°F): 48 hours
Frozen (-20°C/-4°F or below): Unacceptable

Specimen Storage in Department Prior to Disposal:

Refrigerated (2-8°C or 36-46°F): 7 days


Royal Oak Clinical Molecular Pathology Laboratory.


Once per week.
Results available in 7–10 days.

Reference Range

Negative (no gene rearrangement).

Test Methodology

RNA extraction and analysis for BCR-ABL fusion transcript from whole blood or bone marrow using the reverse transcriptase and the polymerase chain reaction (RT-PCR) followed by restriction fragment length analysis.


The test is diagnostic for chronic myeloid leukemia (CML) and is a prognostic indicator in acute lymphoblastic leukemia (ALL) in the adult and pediatric ALL cases.

Clinical Utility

  • This test is used for the detection of BCR-ABL gene rearrangement for the diagnosis and monitoring of CML and ALL patients.
  • The test is required for the diagnosis of CML, also to rule out CML in all other myeloproliferative neoplasms; for ALL patients, both pediatric and adults, the test is recommended for risk stratification.
  • Breakpoints Identified: Minor (p190) - e1a2
                                           Major (p210) - b3a2, b3a3, b2a2

CPT Codes

81206, 81207.


Last Updated


Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.


This directory currently reflects information only for specimens collected and/or processed at the
Farmington Hills, Grosse Pointe, Royal Oak, and Troy campuses.